Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

NCT01737398 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

FAP
Familial Amyloid Polyneuropathy
TTR
Transthyretin
Amyloidosis

Interventions

DRUG: Inotersen
DRUG: Placebo

Sponsor

Ionis Pharmaceuticals, Inc.